Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Dentistry|April 6, 2024
Over-the-counter products in tooth bleaching: A scoping reviewLaryssa Mylenna Madruga Barbosa, Mônica Barbosa Gonçalves Amâncio Filha, Juan Vitor Costa Leite, et al.Journal of Dentistry|October 10, 2023
Scoping review: Effect of surface treatments on bond strength of resin composite repairHermano Nóbrega Macedo Neto, Juan Vitor Costa Leite, Jamyle Moura de Medeiros, et al.Haematologica|July 29, 2017
Prolonged <i>versus</i> standard native <i>E. coli</i> asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose, et al.International Journal of Biological Macromolecules|May 2, 2026
Structural and physicochemical characterization of maltodextrin (starch-derived polysaccharide) microcapsules loaded with phenolic-rich yerba mate extractsMarcos Antonio Matiucci, Vitor Costa Dalagna, Natallya Marques da Silva, et al.Expert Review of Vaccines|June 17, 2020
Impact of a twelve-year rotavirus vaccine program on acute diarrhea mortality and hospitalization in Brazil: 2006-2018Myrela Conceição Santos De Jesus, Victor Santana Santos, Luciane Moreno Storti-Melo, et al.Expert Review of Anticancer Therapy|October 3, 2022
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortiumNira Arad-Cohen, Bernward Zeller, Jonas Abrahamsson, et al.British Journal of Haematology|May 25, 2019
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)Mattias Hofmans, Stefan Suciu, Alina Ferster, et al.Haematologica|July 4, 2015
CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocolFarzaneh Ghazavi, Emmanuelle Clappier, Tim Lammens, et al.Trials|June 19, 2026
CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortiumGertjan J L Kaspers, Merlijn van Hamel, Jonas Abrahamsson, et al.Blood Advances|February 12, 2026
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patientsJean Donadieu, Dmitry Evseev, Francesco Pegoraro, et al.Pageof 4